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Spondyloepiphyseal dysplasia tarda (SEDL) is a genetically heterogeneous disorder characterized by mild-to-mod-
erate short stature and early-onset osteoarthritis. Both autosomal and X-linked forms have been described. Else-
where, we have reported the identification of the gene for the X-linked recessive form, which maps to Xp22.2. We
now report characterization of an exon-skipping mutation (IVS3+5GrA at the intron 3 splice-donor site) in two
unrelated families with SEDL. Using reverse transcriptase (RT)–PCR, we demonstrated that the mutation resulted
in elimination of the first 31 codons of the open reading frame. The mutation was not detected in 120 control X
chromosomes. Articular cartilage from an adult who had SEDL and carried this mutation contained chondrocytes
with abundant Golgi complexes and dilated rough endoplasmic reticulum (ER). RT-PCR experiments using mouse/
human cell hybrids revealed that the SEDL gene escapes X inactivation. Homologues of the SEDL gene include a
transcribed retropseudogene on chromosome 19, as well as expressed genes in mouse, rat,Drosophila melanogaster
Caenorhabditis elegans, and Saccharomyces cerevisiae. The latter homologue, p20, has a putative role in vesicular
transport from ER to Golgi complex. These data suggest that SEDL mutations may perturb an intracellular pathway
that is important for cartilage homeostasis.
Introduction
Spondyloepiphyseal dysplasia tarda (SEDL) is a rare os-
teochondrodysplasia that is first evident in affected in-
dividuals at 3–12 years of age. Clinical features include
short trunk, barrel-shaped chest, and mild-to-moderate
short stature. Premature osteoarthritis is common, es-
pecially in weight-bearing joints (Taybi and Lachman
1990). The X-linked recessive form (SEDL [MIM
313400]) was first reported by Jacobsen (1939), and its
estimated prevalence is 1.7 per million (Wynne-Davies
and Gormley 1985). Rare families exhibiting autosomal
inheritance patterns have also been described (Pfeiffer et
al. 1992; Schantz et al. 1988). Localization of the SEDL
gene to Xp was originally reported by Szpiro-Tapia et
al. (1988) and was further refined to the ∼2-Mb interval
at Xp22, between DXS16 and DXS987, by Heuertz et
al. (1995). The critical region was refined to !170 kb,
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by critical recombination events at DXS16 and
AFMa124wc1, in two Australian families with SEDL
(Gedeon et al. 1999); subsequently, a highly conserved
gene was cloned in silico from a publicly available ge-
nomic sequence. In three unrelated Australian families
with SEDL, different dinucleotide deletions in this gene
were identified that result in frameshifts and generate
premature stop codons.
In the present study, we describe a large North Amer-
ican family with SEDL and confirm the location of the
disease gene to Xp22.2 in this family by two-point link-
age analysis. We demonstrate a mutation at the intron
3 splice-donor site of the SEDL gene in affected indi-
viduals and obligate carriers, and we show evidence for
abnormal splicing of exon 3 in cell lines from an affected
man. We also document the presence of the same mu-
tation in another unrelated patient with SEDL, suggest-
ing that it is a hot spot for mutation within the SEDL
gene. Ultrastructural analysis of articular cartilage from
an adult SEDL patient carrying this mutation demon-
strates unusual chondrocyte histomorphology. Finally,
we show that the SEDL gene escapes X inactivation. Its
homology to the yeast gene that encodes protein p20
(Sacher et al. 1998), a component of the transport pro-
tein particle (TRAPP), leads us to hypothesize that the
SEDL gene product has a key role in trafficking chondro-
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Figure 2 Radiographs of the lateral spine (left) and pelvis (right) of a 31-year-old man (IV:8 in fig. 1) with SEDL. Note platyspondyly
and superior and inferior humping of vertebrae, as well as irregular hip-joint surfaces and short femoral necks.
cyte proteins from endoplasmic reticulum (ER) to Golgi
complexes and therefore is essential for maintaining ho-
meostasis of the cartilage extracellular matrix.
Subjects and Methods
Clinical Summary
The present study was approved by the Institutional
Review Board of Vanderbilt University Medical Center,
and informed consent was obtained from all partici-
pants. The proband of family 1 (V:1 in fig. 1) was a 19-
year-old man who sought medical attention because of
chronic lower back pain. The proband’s height was 173
cm (25th percentile), and his arm span was 187 cm. His
trunk was disproportionately short, and his chest was
barrel-shaped. Facial features were unremarkable, and
results of the neurologic examination were within nor-
mal limits. Radiographs revealed platyspondyly with su-
perior and inferior humping of the vertebral bodies; the
pelvis was somewhat narrow, and the femoral necks
were short. Family history revealed 21 affected males
spread over five generations, a group that constitutes the
largest SEDL pedigree ascertained to date (see fig. 1).
The surnames in the first generation suggest that the
family is of British descent. A maternal first cousin once
removed (IV:8 in fig. 1) underwent replacement of the
right hip joint at age 31 years, as well as replacement
of the left shoulder joint at age 34 years, because of
osteoarthritis. Another maternal male relative (IV:15 in
fig. 1) underwent hip joint replacement at age 50 years.
Five affected men, ages 19–43 years, were examined by
one of us (G.E.T.). Heights were 147–173 cm (mean
SD 159  10 cm), and arm span exceeded height by a
mean SD of 20 12 cm. Radiographs of an affected
man (IV:8 in fig. 1) are shown in figure 2.
Family 2 was ascertained at the Universitatskinder-
klinik in Mainz, Germany. The proband displayed nor-
mal linear growth until he was 6 years of age but, since
that time, has gradually demonstrated disproportionate
short stature. His height at 11.5 years of age was 129
cm (12 SD below the mean for his age; 50th percentile
for 8.5 years), and his arm span exceeded his height by
12 cm. Changes typical of SEDL were also evident on
radiographs. He has an unaffected brother and no other
affected relatives.
Cell Culture, RNA, and DNA Isolation
Patient lymphoblastoid cell lines were grown and
maintained under standard culture conditions. Genomic
DNA was extracted from whole blood, cultured cells,
or dried buccal swabs, using either the Qiagen blood kit
or QIAamp kit (Qiagen). Total RNA was isolated from
cultured cells using method of Chomczynski and Sacci
(1987) or RNeasy kit (Qiagen).
Linkage Analysis
Fifty-two members of family 1, including 10 of 16
living affected males and 12 obligate female carriers,
were genotyped at 18 microsatellite markers spanning
the region from DXS1223 to DXS989 at Xp22.2 (Dib
et al. 1996; GenBank). Two-point analysis was per-
formed using the MLINK program of LINKAGE, ver-
sion 5.2 (Lathrop and Lalouel 1984), assuming X-linked
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Figure 3 Articular cartilage ultrastructure from the femoral head of a 50-year-old man with SEDL (IV:15 in fig. 1) and a 50-year-old
patient with idiopathic osteoarthritis. a, SEDL chondrocyte with dilated rER. Arrows indicate rER, and n indicates nucleus (originalmagnification,
8,140#). b, Chondrocyte from a 50-year-old man with osteoarthritis (original magnification, 8,140#). Note normal nuclear:cytoplasmic ratio
and absence of dilated rER. c, SEDL chondrocyte cytoplasm. The abundant Golgi complexes are indicated by g, and dilated loops of rER are
indicated by arrows (original magnification, 23,830#). d, SEDL extracellular matrix. Arrows indicate collagen fibrils that are short and frayed,
and arrowheads indicate fibrils of variable diameter (original magnification, 23,830#).
recessive inheritance of SEDL with full penetrance and
allele frequency of .00001.
Histologic Analysis
Residual articular cartilage was obtained during hip-
joint replacement in family member IV:15 (fig. 1). Sam-
ples were either frozen or fixed in formalin or buffered
glutaraldehyde and were prepared for histologic analysis
by routine methods (Brodie et al. 1998).
PCR, RT-PCR, and Sequence Determination
PCR was performed on genomic DNA as described
elsewhere (Gedeon et al. 1999), using oligonucleotide
primer pairs designed from the unique X-specific se-
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Figure 4 Splice mutation in SEDL. a, PCR amplification of a fragment of the SEDL gene spanning the exon 3/intron 3 junction. The
mutant allele contains a 5GrA transition at the intron 3 splice-donor site, which disrupts a MaeII restriction site. The proband of family 1
is the affected man in the third generation of the pedigree as drawn. b, Sequencing of cDNA from a lymphoblastoid cell line from the proband
of family 1. Sequencing reveals two transcripts (each missing exon 3, which contains the translational start site).
quence that flanked each of the four coding exons on
the SEDL gene. The RT-PCR experiments were also per-
formed as described by Gedeon et al. (1999). Genomic
DNA was sequenced from both strands, using PCR
primers and ThermoSequenase cycle sequencing kit
(USB).
X-Inactivation Studies
Mouse/human somatic-cell hybrids that retain either
an active or inactive human X chromosome have been
described elsewhere (Brown et al. 1997; Carrel et al.
1999). The SEDL primers used were 5′-AGGAGC-
CATATATTGAAGACCATG-3′ (forward, designated
“5′21F”) and 5′-TCCTGAGTATACACCATTGTGG-3′
(reverse, designated “3′52R”). Possible amplification of
the pseudogene SEDLP (Gedeon et al. 1999; Gecz et al.
2000) was assessed by digesting RT-PCR products with
BsaJ1, which cleaves only the pseudogene amplimer.
Conditions for RT-PCR and oligonucleotide primers for
MIC2 and A007K03 are as described elsewhere (Carrel
et al. 1999).
Linkage of SEDL Phenotype to Xp22 Confirmed
Before the discovery of the SEDL gene, we performed
two-point linkage analysis between the SEDL phenotype
and 18 microsatellite markers at Xp22.2. Peak LOD
scores were obtained at DXS16 and DXS8022 (Zp
and 8.22, respectively, at v p 0), which were later5.71
found to flank the disease locus. However, despite the
large size of the North American pedigree, no recom-
binants were identified that could narrow the candidate
region within the 18-cM span from DXS7109 to
DXS1226. The critical region was subsequently limited
to !170 kb by identifying recombinations in two small
Australian pedigrees (Gedeon et al. 1999).
Histologic Analysis of SEDL Cartilage
Histologic analysis revealed pathologic changes that
are typical of osteoarthritis (Pritzker 1998), including
horizontal fibrillation near the articular surface and oc-
casional clustering of chondrocytes in the resting zone
(data not shown). Cellularity was unremarkable, and
staining with toluidine blue revealed a normal distri-
bution of glycosaminoglycan. Figure 3 shows the ultra-
structure of articular cartilage from the hip joint of a
family 1 member (individual IV:15). The extracellular
matrix contained a normal number of collagen fibrils,
some of which appeared short, frayed, or of variable
diameter. Chondrocytes contained excessive cytoplasm
with abundant Golgi complexes and dilated, rough ER.
In contrast, chondrocytes from an age- and sex-matched
patient with idiopathic osteoarthritis were mostly apop-
totic, with those remaining viable cells demonstrating a
normal nucleus:cytoplasm ratio and no organelles of
unusual appearance.
Splice-Donor–Site Mutation in Intron 3
Direct sequencing of gDNA from the proband of each
family revealed a GrA transition in the fifth base of the
intron 3 splice-donor site. The mutation disrupts aMaeII
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Figure 5 Expression of genes from active or inactive X-containing hybrids. cDNA from mouse/human somatic-cell hybrids that retained
either the human active (Xa) or inactive (Xi) X chromosome was amplified with gene-specific primers. A negative image of ethidium bromide–
stained products separated by agarose gel electrophoresis is shown. Lanes contain human female cell line (lane 1); mouse tsA1S9az31b cell line
(lane 2); t60-12 (lane 3); Aha11aB1 (lane 4); t86-B1maz1b-3a (lane 5); t11-4Aaz5 (lane 6); t75-2maz34-4a (lane 7); t48-1a-Daz4a (lane 8);
LT23-1E2Buv5Cl26-7A2 (lane 9); L23-4B (lane 10); t51-S2 (lane 11); tHM-1a (lane 12); tHM-1d (lane 13); A23-1aCl5 (lane 14); genomic
DNA from a somatic-cell hybrid cell line retaining human chromosome 19 (lane 15). PCR products in all lanes have been digested with BsaJ1
to distinguish SEDL product from pseudogene SEDLP product, since only the latter is cleaved by BsaJ1. Control transcripts A007K03 (which
is subject to inactivation) and MIC2 (which escapes inactivation) demonstrate the inactivation status for each hybrid shown.
restriction site, which allowed us to efficiently screen all
family members (fig. 4a). The mutation cosegregated
with the affected phenotype and in known carriers, with
two exceptions. One was a phenotypically normal 10-
year-old boy (V:9 in fig. 1), and the other was a man
(IV:10 in fig. 1) of normal stature who denied symptoms
of osteoarthritis. Despite repeated inquiries, we were un-
able to obtain radiographs of either individual, and in-
dividual IV:10 was unavailable for physical examina-
tion. The mutation was not seen in 120 control X
chromosomes (CEPH panel) after complete MaeII di-
gestion of gDNA PCR amplimers. The identical muta-
tion was seen in the affected individual and his mother
in family 2 (data not shown). No other sequence changes
were seen in the coding region or flanking intron se-
quences in either proband. No mutations in the SEDL
gene were detected by genomic sequencing of the control
patient with osteoarthritis.
cDNA Pattern in SEDL Lymphoblastoid Cells
The predominant SEDL transcript from several nor-
mal tissues lacks exon 2 (Gedeon et al. 1999; Gecz et
al. 2000). When RT-PCR was performed, using total
lymphoblastoid cell RNA from the proband of family
1, two SEDL transcripts were seen (fig. 4b). The longer
transcript lacked exon 3 but retained exon 2; the shorter
transcript lacked both exon 2 and exon 3. There was
no evidence for the use of alternative splice sites (data
not shown), and no other consensus sequences for trans-
lation initiation (Kozak 1986) are seen in exons 4–6.
Because exon 3 contains the translation start site, we
hypothesize that no SEDL protein is produced from this
mutant allele.
X-Inactivation Studies
Figure 5 illustrates the expression of SEDL in a series
of somatic-cell hybrids that retain either an active or an
inactive human X chromosome. Amplification of EST
A007K03 (which is subject to inactivation [Carrel et al.
1999]) and MIC2 (which escapes inactivation [Brown
et al. 1997]) is shown for comparison. SEDL is expressed
in all cell lines tested, indicating that SEDL escapes X
inactivation. Identity of the RT-PCR product as the
SEDL gene product is further demonstrated by absence
of amplification within the parent mouse cell line (lane
2) and insensitivity to digestion by BsaJ1.
Discussion
Effect of IVS35GrA Mutation on Splicing
The RT-PCR experiments using lymphoblastoid RNA
from the proband in family 1 failed to generate any
transcripts with a normal splicing pattern. Some tran-
scripts retained exon 2, which is usually spliced out
(Gedeon et al. 1999), but the majority of the transcripts
lacked both exon 2 and exon 3. Exon 3 contains the
translation start site, and, although there are five addi-
tional methionine residues in the open reading frame,
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Table 1
IVS+5GrA Mutations Causing Human Diseases
Gene
Mutated
Sequence Intron
No. of bp
Matched
with
Consensusa Reference
SEDL AAgtacat 3 5/8 Present study
b-globin TTgtgaat 1 5/8 Lapoumeroulie et al. 1986
COL3A1 CTgtaaat 27 5/8 Thakker-Varia et al. 1995
COL1A1 CTgtaaat 14 5/8 Bonadio et al. 1990
COL1A2 GTgtgaat 33 5/8 Ganguly et al. 1991
HPRT CTgtaaat 7 5/8 Gibbs et al. 1989
CYBB CGgtaaaa 3 5/8 deBoer et al. 1992
PROS1 TGgtacat 10 5/8 Reitsma et al. 1994
WT1 AAgtgcat 9 5/8 Bruening et al. 1992
BTK TGgtaaat 2 6/8 Duriez et al. 1994
MYBPC3 ACgtgaat 7 6/8 Carrier et al. 1997
CYP17 TGgtgaat 7 6/8 Yamaguchi et al. 1997
HPRT ATgtaaat 8 6/8 Gibbs et al. 1989
a Splice-donor consensus sequence AGgt(a/g)agt derived from 3,274 exon/
intron junctions (Zhang 1998), where capital letters denote last 2 bp of exon.
none has an associated Kozak consensus sequence for
initiation of translation. Therefore, we would not expect
any protein to be translated from this mutant allele. In
addition to the two families reported here, three addi-
tional unrelated families with SEDL have been ascer-
tained that carry this same mutation (Gedeon et al. 2001
[in this issue]). This suggests that the IVS35G residue
may represent a hypermutable site in the SEDL gene.
The thermodynamic data in the literature are inade-
quate for direct calculation of the effect of the
IVS35GrA transition on RNA splicing. However, a
rough estimate is attained by using the consensus se-
quence data compiled by Shapiro and Senapathy (1987).
By use of their method, a score of 76.1 is obtained for
the wild-type allele, whereas a score of 61.7 is obtained
for the mutant allele. For comparison, the human con-
sensus sequence for splice-donor sites (AGgt[a/g]agt)
(Zhang 1998) yields a score of 96–100, depending on
whether adenine or guanine lies in the third position of
the intron. A more convenient way to assess the signif-
icance of splice-donor site substitutions is based on the
analysis of factor IX splice mutations by Ketterling et
al. (1999), where one considers bases 2 to 6 of the
splice site. They propose a “5–6” hypothesis, whereby
normal splicing is expected to be severely compromised
if a donor site matches the consensus sequence at fewer
than seven positions. This is exemplified by the
IVS35GrA transition in SEDL, as well as 12 other
such mutations extracted from OMIM, which are listed
in table 1. Thus, all thirteen mutations lend further sup-
port to Ketterling’s “5–6” hypothesis.
Two clinically normal male subjects in family 1 (V:9
and IV:10 in fig. 1) were shown to harbor the mutant
allele by both haplotype analysis and MaeII restriction
analysis of PCR amplimers. Although V:9 may be pre-
symptomatic, IV:10 is a mature adult who states that
his height is 183 cm and that he has no skeletal com-
plaints. We were unable to obtain radiographs or a cell
sample of either individual and therefore cannot deter-
mine whether IV:10 is mildly affected or has normal
SEDL transcripts in his tissue.
Significance of SEDL Escaping X Inactivation
The data in figure 5 clearly indicate that the SEDL
gene escapes X inactivation. The closest flanking genes
identified at Xp22.2 (Rab9 and Cxorf5) also escape X
inactivation (Carrel et al. 1999). This clustering further
supports a model in which regional mechanisms may
control the expression of genes that escape X inactiva-
tion (Miller and Willard 1998; Carrel et al. 1999). The
majority of the mutations in SEDL patients characterized
thus far (Gedeon et al. 1999 and 2001; Mumm et al.
2000; and the present study) are predicted to severely
truncate or eliminate the protein product. The obser-
vation that SEDL escapes X inactivation suggests that
haploinsufficiency at the locus is inadequate to produce
any phenotypic changes in female SEDL carriers. Al-
thoughWhyte et al. (1999) observed subtle radiographic
changes in older SEDL carriers, no signs or symptoms
of premature osteoarthritis were noted in the women of
the family reported here or in those described in the
report by Gedeon et al. (1999).
Putative Role for SEDL Gene Product, Sedlin
The SEDL gene is highly conserved, and homologues
are found in mouse, rat, Caenorhabditis elegans, Dro-
sophila melanogaster, and Saccharomyces cerevisiae
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(Gedeon et al. 1999). The yeast homologue, designated
p20 or YBR254c, shares 41% identity and 57% amino
acid similarity with human SEDL (Sacher et al. 1998).
Yeast p20 is a 20-kD hydrophilic protein which is part
of a complex of 10 proteins constituting TRAPP. The
TRAPP complex has been shown to play a key role in
transport of yeast proteins from the ER to the Golgi
apparatus (Barrowman et al. 2000). A precedent for hu-
man disease in such a transport process has been estab-
lished by combined deficiency of factors V and VII
(Nichols and Ginsburg 1999). This autosomal recessive
coagulopathy results from mutations in the ERGIC-53
gene, which encodes a transmembrane glycoprotein–
binding component of the ER-Golgi intermediate com-
partment (ERGIC). Mutations in ERGIC-53 result in
impaired secretion of clotting factors V and VIII from
megakaryocytes and hepatocytes.
Transient transfection experiments with FLAG- or
GFP-tagged SEDL (Gecz et al. 2000) suggested locali-
zation of the SEDL protein to perinuclear structures,
whereas transfection with truncating mutant transcripts
disrupted this localization. Furthermore, the appearance
of SEDL chondrocytes from articular cartilage (fig. 3)
suggests that there may be disruption in cellular traf-
ficking between rER and Golgi. Since the histopathology
of SEDL cartilage has not been described elsewhere, it
is uncertain whether the cellular architecture depicted in
figure 3 is representative of this genetic disorder. The
cellular appearance is dissimilar to the gross dilation of
rER that is seen as a result of any of the following:
retention of abnormal type II collagen in patients with
spondyloepiphyseal dysplasia congenita (Tiller et al.
1995), abnormal type IX collagen in some patients with
multiple epiphyseal dysplasia (Spayde et al. 2000), or
abnormal COMP in patients with pseudoachondro-
plasia (Rimoin et al. 1994). Such ultrastructural abnor-
malities are not seen in fibroblasts of patients with these
three disorders, since the abnormal protein is not pro-
duced appreciably in fibroblasts. Although the human
SEDL gene appears to be expressed ubiquitously, we
propose that the tissue-specific nature of the SEDL
phenotype may lie in the protein cargo that is trans-
ported by the TRAPP system in chondrocytes. Delin-
eation and further study of additional SEDL mutations
(Gedeon et al. 2001 [in this issue]) may reveal critical
motifs within the SEDL protein structure and afford us
a better understanding of its function.
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